Home > Focus Areas > COPD Connect > Post
  • Saved

2w
How updated GOLD 2026 guidance is shaping long-term COPD control

GOLD 2026 reframes how long-term COPD control is approached in clinical practice. Beyond spirometry alone, the updated guidance places greater emphasis on sustained symptom control, exacerbation prevention, and preservation of functional capacity—recognizing that airflow limitation and day-to-day disease impact do not always move in parallel.

The 2026 update more clearly distinguishes between initial and follow-up treatment pathways and emphasizes identifying future risk earlier in the disease course. Even a single moderate exacerbation is recognized as a meaningful risk signal, reinforcing a proactive strategy focused on early initiation of maintenance therapy to stabilize disease and reduce future events rather than reacting to repeated exacerbations.

Bronchodilation remains central to COPD management under GOLD 2026. Dual long-acting bronchodilation (LABA + LAMA) is recommended as preferred initial therapy for high-risk Group E, rather than initiating triple therapy. GOLD 2026 does not recommend initiating treatment with triple therapy as routine initial management. Instead, inhaled corticosteroids are added selectively—primarily in patients with blood eosinophil counts ≥300 cells/µL—highlighting that ICS use is conditional and not part of universal initial management. Because many symptomatic patients fall within Groups B and E, sustained dual bronchodilation remains foundational to long-term disease control.

As GOLD 2026 places greater weight on longitudinal assessment across the disease continuum, integrating symptoms, exacerbation history, lung function, and functional capacity into routine follow-up remains essential.

Which GOLD 2026 updates have most influenced how you assess long-term COPD control? Where does long-acting bronchodilation fit into your current approach to maintaining control?

 

Profile Image
  • 2w
    At this point the early threshold for group E is extremely important. This will facilitate earlier use of triple RX
    The use of biologics and Ohtuvayre will just add more options to enhance control which is really what the patients are sensitive to. Early ex is optimal RX
    Jason Karp MD
  • 2w
    Definitely agree the use of LAMA/LABA as early treatment and also using inhaled corticosteroids based on eosinophil counts. Am much more aware of Eosinophil counts more than ever
  • 3w
    I have begun to initially prescribe more LAMA/LABA. I will have a low threshold to add ICS for patients with ongoing symptoms despite LAMA/LABA and have chronic cough/bronchitis symptoms. I am checking more FeNOs in the office to see who might benefit from ICS if they are not already on it or who might benefit from the addition of a biologic.
  • 1mo
    Utilize dual and triple therapy often and try to adhere to the guidelines when possible although out of pocket expenses is quite an obstacle
  • 1mo
    I usually follow the recommendations
    I usually needs to play around which combinations of inhaler are covered by insurance
  • 1mo
    I been using this guideline without any issue.
  • 1mo
    I find it interesting that use of ICS as maintenance therapy is not promoted as I have been led to believe that the only class of therapy showing mortality benefit is the triple maintenance therapy. The updated guidelines focusing on exacerbation reduction and functionality will be considered and promote initial maintenance with Lama/Laba therapy.
  • 1mo
    Biggest issues we face is coverage many once daily bronchodilator lama laba s not covered and even split difficulty guidelines are but too issuance companies don’t follow them
  • 1mo
    Bronchodilator therapy is best initial option
    Also try to determine triggering events and decrease the
    Regular follow up and monitor PFT's
    and fight the insurers to get what is the best treatment
    option for the patients
  • 1mo
    I've been employing these guidelines and am lucky that I typically don't have problems getting patients on Trelegy.
  • 1mo
    I’m sorry, but we have serious problems getting these inhalers covered by patients insurance. Very difficult to get a LABA/LAMA. Completely forget about trying to get Trelegy covered. I prescribed Atrovent to a patient this week and even that was not affordable to her. It’s hard to follow the GOLD criteria in situations like this.
  • 1mo
    I have been using these guidelines before they were written
  • 1mo
    Fully assess a new COPD patient-assess to what degree they have been asthma component, chronic bronchitis component, emphysema component of bronchiectatic component and adjust therapy accorddingly. For instance, if. Emphysematous component, then LABA/LABA therapy, and if COPD/asthma overlap then initiate ICS and consider Biologics
  • 1mo
    I would prefer dual inhaler since they are available in generic
  • 1mo
    lama and laba is always in my arsenal for treatment of chronic copd or patients with frequent exacerbations
  • 1mo
    Biologics are very important in the treatment and need to be added in guidelines in providing technology to patients
  • 1mo
    It is encouraging to have biologics in the GOLD guidelines which are for patients that have an eosinophilic component.
    I also plan on keeping long acting bronchodilators in conjunction with them given their effectiveness as well.
  • 1mo
    I would prefer using the dual inhalers since they've gone generic it's been affordable to more patients but medicare patients are an exception. Triple therapy inhaler can be useful when dual inhaler isn't meeting the measures. I'd prefer using dual for as long as possible first and work on quitting smoking.
  • 1mo
    Preventing exacerbations and preserving lung function is key in COPD management. Both TRELEGY and BREZTRI tout improvement in lung function and reductions in exacerbations . Usually Class B patients respond well to a dual bronchodilator but I find myself prescribing a triple therapy often in class E COPD patients.
  • 1mo
    LABA/LAMA combination years ago made it much easier to maximize bronchodilation (back in the day when VA decided ADVAIR was too expensive & we used Foradil & Asmanex). Prior to that use of 2 inhalers was cost prohibitive for a lot of my patients. Much better symptom control with dual BDs. The addition of steroid typically reserved for exacerbations or uncontrolled symptoms back then. Now with the 2 triple options & dual LABA/LAMA much more likely to push therapy up for better control without as much worry about cost/benefit for patients. Use of ICS is up especially those at higher risk or exacerbations now given the single copay need.
  • 1mo
    I would say using dual bronchodilators more rather than triple therapy (including inhaled steroids as part of preventative therapy) is how I have changed my practice with these new guidelines. I have found, however, that with my large Medicare population, these products are expensive and often not well covered under their drug plans. This makes it challenging to approach my COPD patients with these initial preventative recommendations/routine management.
  • 1mo
    I am always using triple therapy for my patients with COPD and really emphasizing need to quit smoking. I am more aware of need to prevent exacerbations than previously
  • 1mo
    Frequency of annual exacerbation is the biggest adjustment I need to make on management of my patients with COPD. It's possible to treat those patients with newly FDA approved Ensifentrine and biological therapies now.
  • 1mo
    I am more aggressive in starting maintenance therapy after an exacerbation. I feel vindicated in my previous preference of LABA+LAMA as usual therapy, I question guidance away from triple therapy for frequent exacerbators.
  • 1mo
    I agree- The concept of preventing exacerbation represents a shift in thinking.:
    Bronchodilation over inflammation control is also a change.
    Moving away from triple therapy
    More use of anti-inflammatories
  • 1mo
    I like LAMA/LABA therapy for long term bronchodilation in my patients who do not have significant exacerbations or inflammatory symptoms.

    Not mentioned in the above summary is the inclusion of biologic therapy for appropriate patients to prevent exacerbations. I believe these are useful in a minority of patients in my practice with COPD, at least with the current available agents.
  • 1mo
    So the first idea of preventing exacerbation is a change in paradigm.

    Second : Bronchodilation over inflammation control is a change as well.
    Not sure about the move away from triple therapy since that ignores the mortality data.
  • 1mo
    COPD control is not the absence of symptoms — it’s the absence of destabilization.

    That includes:
    • Preventing that “first” moderate exacerbation from becoming a pattern
    • Avoiding acceleration of functional decline
    • Preserving independence
  • 1mo
    COPD is a progressive disease spectrum in particular when pt conitnues to smoke or other factors like alpha 1 antitryptisin deficeincy is present so these factors are important in evaluating COPD and the management ! Then there is the element of Asthma that needs to be considered as well in choosing the therapy ! Smoking needs to be stopped at any cost to prevent the progression at any cost and no therapy is going to counteract that ! Bronchodilatation is the cornerstone of the therapy and LAMA /LABA combination is the initial therapy introduction of ICS where allergic or inflmatory component is present clnically or with eosinophilic component or any exacerbation So GOLD 2026 guidlines are quite clinically oriented and gives the discretion to use ICS in the progressive disease process and for optimal lung fuction improvement and It is important to taper off the ICS in stable COPD due course of time with the continued improvement

Show More Comments